Spero Therapeutics News

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics with a Overweight.

Analyst UpgradesApr 4 21:45

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics with a Buy and maintains $7 price target.

Analyst UpgradesMar 18 19:02

Spero Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei

BenzingaMar 18 19:01

Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating

TipRanksMar 18 18:26

Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Yahoo FinanceMar 17 21:01

Spero Therapeutics Files $300M Mixed Securities Shelf

Seeking AlphaMar 16 04:45

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Yahoo FinanceMar 15 18:49

Earnings Call: Spero Therapeutics Reports Solid 2023 Financials, Advances RD

InvestingMar 15 09:30

Spero Therapeutics, Inc. (SPRO) Sees Surge in Pre-Market Trading

Spero Therapeutics, Inc. (NASDAQ: SPRO), a pioneering biopharmaceutical company specializing in treatments for bacterial infections and rare diseases, experienced a remarkable pre-market surge on Thursday, following a static day on Wednesday. The stock exhibited a sudden climb of 15%, indicating significant investor interest. This surge appears to be directly linked to the recent earnings release. ...

Stocks TelegraphMar 14 20:37

Spruce Biosciences SPRB Topline Data; Spero Therapeutics SPRO Earnings

BioPharmCatalystMar 14 20:16

Q4 2023 Spero Therapeutics Inc Earnings Call

Yahoo FinanceMar 14 18:33

TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)

TipRanksMar 14 11:25

Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference

The following is a summary of the Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript:Financial Performance:Spero Therapeutics reported having cash and cash equivalents worth $76.3 millio

Futu NewsMar 14 05:55 · Conference Call

Recap: Spero Therapeutics Q4 Earnings

Spero Therapeutics (NASDAQ:SPRO) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsSpero Therapeutics beat est

BenzingaMar 14 04:15

Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of

BenzingaMar 14 04:12

Spero Therapeutics Reiterates Expected Cash Runway Into Late 2025 >SPRO

Spero Therapeutics Reiterates Expected Cash Runway Into Late 2025 >SPRO

Dow JonesMar 14 04:03

Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, Vs. Street Est of $18.6M

04:02 PM EDT, 03/13/2024 (MT Newswires) -- Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M

MT NewswiresMar 14 04:02

Spero Therapeutics 4Q Rev $73.5M >SPRO

Spero Therapeutics 4Q Rev $73.5M >SPRO

Dow JonesMar 14 04:01

Earnings Scheduled For March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec

BenzingaMar 13 18:15

Spero Therapeutics Q4 2023 Earnings Preview

Seeking AlphaMar 13 05:35